JP2009528070A5 - - Google Patents

Download PDF

Info

Publication number
JP2009528070A5
JP2009528070A5 JP2008557519A JP2008557519A JP2009528070A5 JP 2009528070 A5 JP2009528070 A5 JP 2009528070A5 JP 2008557519 A JP2008557519 A JP 2008557519A JP 2008557519 A JP2008557519 A JP 2008557519A JP 2009528070 A5 JP2009528070 A5 JP 2009528070A5
Authority
JP
Japan
Prior art keywords
mir
gene product
pancreatic cancer
composition
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008557519A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009528070A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/063208 external-priority patent/WO2007103808A2/en
Publication of JP2009528070A publication Critical patent/JP2009528070A/ja
Publication of JP2009528070A5 publication Critical patent/JP2009528070A5/ja
Pending legal-status Critical Current

Links

JP2008557519A 2006-03-02 2007-03-02 膵臓癌に関連するマイクロｒｎａ発現プロファイル Pending JP2009528070A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77827106P 2006-03-02 2006-03-02
PCT/US2007/063208 WO2007103808A2 (en) 2006-03-02 2007-03-02 Microrna expression profile associated with pancreatic cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012188756A Division JP5841024B2 (ja) 2006-03-02 2012-08-29 膵臓癌に関連するマイクロｒｎａ発現プロファイル

Publications (2)

Publication Number Publication Date
JP2009528070A JP2009528070A (ja) 2009-08-06
JP2009528070A5 true JP2009528070A5 (cg-RX-API-DMAC7.html) 2011-04-21

Family

ID=38475730

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008557519A Pending JP2009528070A (ja) 2006-03-02 2007-03-02 膵臓癌に関連するマイクロｒｎａ発現プロファイル
JP2012188756A Expired - Fee Related JP5841024B2 (ja) 2006-03-02 2012-08-29 膵臓癌に関連するマイクロｒｎａ発現プロファイル
JP2013023199A Pending JP2013081483A (ja) 2006-03-02 2013-02-08 膵臓癌に関連するマイクロｒｎａ発現プロファイル

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012188756A Expired - Fee Related JP5841024B2 (ja) 2006-03-02 2012-08-29 膵臓癌に関連するマイクロｒｎａ発現プロファイル
JP2013023199A Pending JP2013081483A (ja) 2006-03-02 2013-02-08 膵臓癌に関連するマイクロｒｎａ発現プロファイル

Country Status (7)

Country Link
US (4) US20100286232A1 (cg-RX-API-DMAC7.html)
EP (6) EP2522750A1 (cg-RX-API-DMAC7.html)
JP (3) JP2009528070A (cg-RX-API-DMAC7.html)
AU (1) AU2007223311C1 (cg-RX-API-DMAC7.html)
CA (1) CA2638844C (cg-RX-API-DMAC7.html)
ES (1) ES2448491T3 (cg-RX-API-DMAC7.html)
WO (1) WO2007103808A2 (cg-RX-API-DMAC7.html)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1771563A2 (en) 2004-05-28 2007-04-11 Ambion, Inc. METHODS AND COMPOSITIONS INVOLVING MicroRNA
EP1838852A2 (en) 2004-11-12 2007-10-03 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
CA2603881A1 (en) 2005-04-04 2006-10-12 The Board Of Regents Of The University Of Texas System Micro-rna's that regulate muscle cells
EP2115138A2 (en) * 2006-09-19 2009-11-11 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
US20100144850A1 (en) * 2007-04-30 2010-06-10 The Ohio State University Research Foundation Methods for Differentiating Pancreatic Cancer from Normal Pancreatic Function and/or Chronic Pancreatitis
EP2198050A1 (en) 2007-09-14 2010-06-23 Asuragen, INC. Micrornas differentially expressed in cervical cancer and uses thereof
NZ585209A (en) 2007-11-09 2012-08-31 Univ Texas Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
WO2009117418A2 (en) 2008-03-17 2009-09-24 The Board Of Regents Of The University Of Texas System Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
EP2285960B1 (en) 2008-05-08 2015-07-08 Asuragen, INC. Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis
WO2010062706A2 (en) 2008-10-30 2010-06-03 Caris Mpi, Inc. Methods for assessing rna patterns
EP4219760A3 (en) * 2008-11-10 2023-09-06 Battelle Memorial Institute Methods, compositions, and devices utilizing microrna to determine physiological conditions
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
EP2730662A1 (en) 2008-11-12 2014-05-14 Caris Life Sciences Luxembourg Holdings Methods and systems of using exosomes for determining phenotypes
WO2010055487A2 (en) * 2008-11-13 2010-05-20 Koninklijke Philips Electronics N.V. Compositions and methods for micro-rna expession profiling of colorectal cancer
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
WO2011150855A1 (en) * 2010-06-04 2011-12-08 Fudan University Micro-rna biomarkers and methods for diagnosis of early colorectal carcinoma and high-grade adenoma
EP3369817A1 (en) 2010-07-06 2018-09-05 InteRNA Technologies B.V. Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma , or in diseases or conditions with activated braf pathway
CN103221542A (zh) * 2010-09-27 2013-07-24 萨班哲大学 miRNA用于诊断、预防、治疗和追踪涉及巨自噬异常的疾病的用途
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
EP2800820B1 (en) 2011-12-19 2020-04-08 Valley Health System Methods and kits for detecting subjects having pancreatic cancer
EP2798089B1 (en) 2011-12-30 2018-05-23 Bio-rad Laboratories, Inc. Methods and compositions for performing nucleic acid amplification reactions
WO2013170146A1 (en) 2012-05-10 2013-11-14 Uab Research Foundation Methods and compositions for modulating mir-204 activity
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
US20150344961A1 (en) * 2012-09-11 2015-12-03 New York University Sera Based miRNAs as Non-Invasive Biomarkers in Melanoma
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
LT3138910T (lt) * 2012-12-06 2017-11-10 Sigma-Aldrich Co. Llc Crispr pagrįstas genomo modifikavimas ir reguliavimas
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
EP3434774A1 (en) 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
KR101501562B1 (ko) * 2013-04-05 2015-03-11 연세대학교 산학협력단 췌장암 진단 마커를 검출하는 방법
US20150018230A1 (en) * 2013-06-11 2015-01-15 Indiana University Research And Technology Corp. PLASMA miRNA SIGNATURE FOR THE ACCURATE DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA
JP6611411B2 (ja) * 2013-12-05 2019-11-27 東レ株式会社 膵臓がんの検出キット及び検出方法
EP3108012A4 (en) 2014-02-18 2017-10-11 Baylor Research Institute Mir-320e and colorectal cancer
EP3115467B1 (en) 2014-03-04 2019-01-02 Hiroshima University Method for assisting detection of pancreatic cancer
WO2015182781A1 (ja) * 2014-05-30 2015-12-03 東レ株式会社 膵臓がんの検出キット又はデバイス及び検出方法
US9623040B2 (en) 2014-07-14 2017-04-18 The Board Of Trustees Of The Leland Stanford Junior University Immunomodulation by controlling expression levels of microRNAs in dendritic cells
WO2016077125A1 (en) 2014-11-10 2016-05-19 Moderna Therapeutics, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
JP2016123340A (ja) * 2014-12-26 2016-07-11 株式会社エバンス 膵癌治療感受性の診断方法及び膵癌治療感受性の増強剤
US20210206818A1 (en) 2016-01-22 2021-07-08 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
EP3438284B1 (en) 2016-03-31 2021-12-22 Toray Industries, Inc. Kit or device for detecting early stage pancreatic cancer or pancreatic cancer precursor lesions and detection method therefor
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
ES2941411T3 (es) 2016-05-18 2023-05-22 Modernatx Inc Polinucleótidos que codifican interleucina-12 (IL12) y usos de los mismos
EP3468537A1 (en) 2016-06-14 2019-04-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2017222958A1 (en) * 2016-06-20 2017-12-28 Kura Oncology, Inc. Treatment of squamous cell carcinomas with inhibitors of erk
ES2989940T3 (es) 2016-06-29 2024-11-28 Crispr Therapeutics Ag Materiales y métodos para el tratamiento de la ataxia de Friedreich y otros trastornos relacionados
WO2018002812A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders
WO2018002762A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
AU2017292169B2 (en) 2016-07-06 2021-12-23 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
EP3481857A1 (en) 2016-07-06 2019-05-15 Crispr Therapeutics AG Materials and methods for treatment of pain related disorders
AU2017347837A1 (en) 2016-10-26 2019-06-06 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
AU2018214556A1 (en) 2017-02-01 2019-08-15 Modernatx, Inc. Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutation peptides
US20200040061A1 (en) 2017-02-22 2020-02-06 Crispr Therapeutics Ag Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
US11559588B2 (en) 2017-02-22 2023-01-24 Crispr Therapeutics Ag Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders
EP3585900B1 (en) 2017-02-22 2022-12-21 CRISPR Therapeutics AG Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
CN119351474A (zh) 2017-02-22 2025-01-24 克里斯珀医疗股份公司 用于基因编辑的组合物和方法
US11407997B2 (en) 2017-02-22 2022-08-09 Crispr Therapeutics Ag Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
WO2018231990A2 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
CA3073211A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
WO2019102381A1 (en) 2017-11-21 2019-05-31 Casebia Therapeutics Llp Materials and methods for treatment of autosomal dominant retinitis pigmentosa
WO2019117269A1 (ja) 2017-12-13 2019-06-20 国立大学法人広島大学 膵がんの検出を補助する方法
JP7402163B2 (ja) 2017-12-21 2023-12-20 クリスパー セラピューティクス アーゲー ２ａ型アッシャー症候群の処置のための材料および方法
EP3746052A1 (en) 2018-01-30 2020-12-09 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
US20210163928A1 (en) 2018-04-11 2021-06-03 Modernatx, Inc. Messenger rna comprising functional rna elements
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
AU2020235865A1 (en) 2019-03-08 2021-09-23 Obsidian Therapeutics, Inc. Human carbonic anhydrase 2 compositions and methods for tunable regulation
US20230194472A1 (en) * 2019-04-26 2023-06-22 Osaka University Microrna analysis using tunneling current
EP3987027A1 (en) 2019-06-24 2022-04-27 ModernaTX, Inc. Endonuclease-resistant messenger rna and uses thereof
MA56517A (fr) 2019-06-24 2022-04-27 Modernatx Inc Arn messager comprenant des éléments d'arn fonctionnels et leurs utilisations
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
MX2022009410A (es) 2020-01-31 2022-10-18 Modernatx Inc Metodos de preparacion de nanoparticulas lipidicas.
US11965162B2 (en) * 2020-04-16 2024-04-23 The Johns Hopkins University MicroRNA and inhibitors thereof and methods of treatment
WO2021262919A2 (en) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
US20230272481A1 (en) * 2020-07-16 2023-08-31 Kurume University Use of microrna as pancreatic cancer biomarker
WO2022020811A1 (en) 2020-07-24 2022-01-27 Strand Therapeutics, Inc. Lipidnanoparticle comprising modified nucleotides
US20230277457A1 (en) 2020-08-06 2023-09-07 Modernatx, Inc. Methods of preparing lipid nanoparticles
US20240166707A1 (en) 2021-01-08 2024-05-23 Strand Therapeutics Inc. Expression constructs and uses thereof
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
US12037616B2 (en) 2022-03-01 2024-07-16 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions
KR20250004731A (ko) 2022-04-26 2025-01-08 스트랜드 세러퓨틱스 인코포레이티드 베네수엘라 말 뇌염 (vee) 레플리콘을 포함하는 지질 나노입자 및 이의 용도
WO2024026487A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Lipid nanoparticle compositions comprising phospholipid derivatives and related uses
WO2024026475A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses
EP4561546A1 (en) 2022-07-29 2025-06-04 ModernaTX, Inc. Lipid nanoparticle compositions comprising surface lipid derivatives and related uses
WO2024222859A1 (zh) 2023-04-28 2024-10-31 深圳深信生物科技有限公司 经修饰的递送载体及其应用
WO2024259373A1 (en) 2023-06-14 2024-12-19 Modernatx, Inc. Compounds and compositions for delivery of therapeutic agents
WO2025160381A1 (en) 2024-01-26 2025-07-31 Modernatx, Inc. Methods of preparing lipid nanoparticles
WO2025166202A1 (en) 2024-01-31 2025-08-07 Modernatx, Inc. Lipid nanoparticle compositions comprising sialic acid derivatives and the uses thereof
ES3048857A1 (es) * 2024-06-10 2025-12-11 Fundacion Para La Investig E Innovacion Biosanitaria Del Principado De Asturias Finba FIRMA DE miRNA UTILES EN LA DISCRIMINACION DE TUMORES
CN119391860B (zh) * 2024-12-25 2025-03-21 慧算基因科技(上海)有限公司 一种用于胰腺癌术后mrd检测及动态监测的引物探针组合物、试剂盒及应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1990A (en) 1841-02-20 Head-block of sawmills for sawing without stub-shot and gaging the
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE120497T1 (de) 1988-05-09 1995-04-15 Univ Temple Verfahren zur voraussage der wirksamkeit einer antineoplastichen behandlung bei einzelnen patienten.
AU647741B2 (en) 1989-12-01 1994-03-31 Regents Of The University Of California, The Methods and compositions for chromosome-specific staining
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6232068B1 (en) 1999-01-22 2001-05-15 Rosetta Inpharmatics, Inc. Monitoring of gene expression by detecting hybridization to nucleic acid arrays using anti-heteronucleic acid antibodies
DE60140676D1 (de) 2000-03-30 2010-01-14 Massachusetts Inst Technology Mediatoren von rns-interferenz, die rns-sequenzspezifisch sind
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
CA2450379A1 (en) * 2001-06-10 2002-12-19 Irm Llc Molecular signatures of commonly fatal carcinomas
CA2462144C (en) * 2001-09-28 2016-09-20 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Micro-rna molecules
US8119610B2 (en) 2002-05-31 2012-02-21 The Regents Of The University Of California Method for efficient RNA interference in mammalian cells
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
EP1534490B1 (en) 2002-08-21 2006-08-02 Mihaly Rigo equipment for manufacturing pipe-couplings and pipe couplings
US20050260639A1 (en) * 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
CA2504605C (en) * 2002-11-13 2016-01-19 Thomas Jefferson University Treatment of chronic lymphocytic leukemia and prostate cancer with microrna mir15
US7906326B2 (en) * 2003-05-07 2011-03-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides associated with alzheimer's disease and uses thereof
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US8106180B2 (en) * 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
US20050142581A1 (en) * 2003-09-04 2005-06-30 Griffey Richard H. Microrna as ligands and target molecules
EP1713938A2 (en) * 2004-02-09 2006-10-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
US20050182005A1 (en) * 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
US7365058B2 (en) * 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
WO2006033020A2 (en) 2004-04-26 2006-03-30 Rosetta Genomics Ltd. Methods and apparatus for the detection and validation of micrornas
EP1771563A2 (en) * 2004-05-28 2007-04-11 Ambion, Inc. METHODS AND COMPOSITIONS INVOLVING MicroRNA
US7635563B2 (en) * 2004-06-30 2009-12-22 Massachusetts Institute Of Technology High throughput methods relating to microRNA expression analysis
WO2006034387A1 (en) 2004-09-21 2006-03-30 Applera Corporation TWO-COLOR REAL-TIME/END-POINT QUANTITATION OF MICRORNAS (miRNAs)
CN103361424A (zh) * 2006-01-05 2013-10-23 俄亥俄州立大学研究基金会 胰腺内分泌和腺泡肿瘤中的微小rna表达异常
US20110320392A1 (en) * 2009-03-02 2011-12-29 Black Esther P Methods for predicting cancer response to egfr inhibitors
US20130310276A1 (en) * 2010-12-22 2013-11-21 Ruprecht-Karls University of Heidelberg Microrna for diagnosis of pancreatic cancer
US9644241B2 (en) * 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
WO2014055117A1 (en) * 2012-10-04 2014-04-10 Asuragen, Inc. Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions

Similar Documents

Publication Publication Date Title
JP2009528070A5 (cg-RX-API-DMAC7.html)
US12077803B2 (en) MicroRNAs as biomarkers for endometriosis
US11959143B2 (en) MicroRNA profiling for diagnosis of dysplastic nevi and melanoma
CA2638844C (en) Microrna expression profile associated with pancreatic cancer
US20180230546A1 (en) Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers
EP2634266B1 (en) miRNA biomarkers of prostate disease
US20150376711A1 (en) Methods of detecting lung cancer
US20110160290A1 (en) Use of extracellular rna to measure disease
WO2010069129A1 (zh) 非小细胞肺癌标记物及其检测方法、试剂盒和生物芯片
JP2012231801A5 (cg-RX-API-DMAC7.html)
CN107109474B (zh) 用于核酸检测的方法和组合物
CN100999765A (zh) 以微小核糖核酸的变化鉴定结肠癌化程度的生物芯片
HK40011172A (en) Micrornas as biomarkers for endometriosis
HK40011172B (en) Micrornas as biomarkers for endometriosis